Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
64 results about "Par 1 antagonist" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Protease-activated receptor-1 (PAR-1) antagonists are known to be potent antiplatelet agents that are also complementary to other antiplatelet therapies. Vorapaxar and atopaxar are currently the two PAR-1 antagonist antiplatelet agents that have undergone extensive clinical development.
The invention relates to the field of medicine relevant to thrombotic diseases, in particular to a PAR-1 antagonist containing an anilino group and a dieneadamantane structure and a preparation method and application of the PAR-1 antagonist. According to the general formula (please see the specification), R<1> and R<2> are selected from an alkyl group of H and an alkyl group of C1-C5 respectively.
The invention relates to the field of thrombotic disease related medicines. Specifically, the invention relates to a terminal alkoxy phenyl substituted trans-cyclohexaneamide structured PAR-1 antagonist, a preparation method thereof and application of the antagonist in preparation of medicines for treating thrombotic diseases, wherein R is selected from C1-C3 alkyl and C3-C5 cycloalkyl.
The invention relates to the field of thrombotic disease related medicines. Specifically, the invention relates to a trans-cyclohexaneamide structured PAR-1 antagonist containing structures, such as alkoxy substituted pyridyl and the like, a preparation method of the antagonist and application of the antagonist in preparation of medicines for treating thrombotic diseases, wherein R is selected from C1-C3 alkyl and C3-C5 cycloalkyl.
The invention relates to the field of thrombotic disease related medicines. Specifically, the invention relates to a terminal alkoxy phenyl substituted trans-cyclohexaneamide structured PAR-1 antagonist, a preparation method thereof and application of the antagonist in preparation of medicines for treating thrombotic diseases, wherein R is selected from C1-C3 alkyl and C3-C5 cycloalkyl.